Abnormal Blood Sugar and HPV Together Triple Cervical Cancer Risk, Finds New Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-11-24 15:15 GMT   |   Update On 2025-11-24 15:15 GMT
Advertisement

China: A recent study published in Frontiers in Endocrinology has revealed that dysglycemia and human papillomavirus (HPV) infection act synergistically to increase the risk of cervical cancer, with the cell proliferation marker Ki-67 potentially mediating this link.

The research, conducted by Yulong Zhang and colleagues from the Department of Gynecology, Fujian Maternity and Child Health Hospital, Fujian Medical University, Fuzhou, China, investigated how abnormal blood glucose levels interact with HPV infection to influence cervical carcinogenesis. While both HPV infection and dysglycemia are known independent risk factors for cervical cancer, their combined impact and underlying mechanisms have remained unclear until now.
Advertisement
The study included women with abnormal cervical screening results who underwent colposcopy and conization at Fujian Maternity and Child Health Hospital’s Cervical Disease Center between June 2018 and June 2023. Using statistical and regression analyses, the researchers examined associations between HPV infection, hyperglycemia, and different stages of cervical lesions, including low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL), as well as invasive cervical cancer. Interaction and mediation models were applied to determine the role of Ki-67 in these associations.
Among the 4,115 participants analyzed, 573 had hyperglycemia alone, 1,479 were HPV-positive, and 548 had both conditions. The study led to the following findings:
  • Women with prediabetes had a 2.47-fold higher risk of developing cervical cancer, while those with diabetes had a 3.67-fold higher risk.
  • Participants with both hyperglycemia and HPV infection showed over a threefold increased risk (OR: 3.12) compared with HPV-positive women with normal glucose levels.
  • A strong synergistic interaction between dysglycemia and HPV infection was identified, with an attributable proportion (AP) of 0.69 and a synergy index (SI) of 3.27.
  • The combined impact of dysglycemia and HPV was significantly greater than their individual effects.
  • Ki-67 expression, a marker of cellular proliferation, mediated around 40% of the effect of hyperglycemia, 37% of the effect of HPV, and over 55% of their combined impact.
  • Dysglycemia and HPV together exerted a significant indirect influence on Ki-67 levels (estimate: 0.08).
According to the authors, these results emphasize the importance of integrated screening and management strategies targeting both glucose abnormalities and HPV infection in women. They emphasized that the dual presence of dysglycemia and HPV markedly amplifies cervical cancer risk, likely through Ki-67–mediated pathways.
The study highlights the potential of Ki-67 as a biological mediator linking metabolic dysfunction and viral oncogenesis. The researchers suggest that future investigations should focus on clarifying the molecular mechanisms involved and exploring therapeutic strategies aimed at modulating Ki-67–related pathways. Such approaches could help reduce cervical cancer risk in women affected by both HPV infection and metabolic disorders like prediabetes and diabetes.
Reference:
Zhang, Y., Zhang, J., Li, H., Zhuang, Y., You, Q., Su, Y., Zheng, X., & Li, S. (2025). Synergistic impact of dysglycemia and HPV on cervical cancer risk: A potential mediating role of Ki-67. Frontiers in Endocrinology, 16, 1422881. https://doi.org/10.3389/fendo.2025.1422881


Tags:    
Article Source : Frontiers in Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News